Skip to content

Clinical Trial Protocol to Evaluate the Efficacy and Safety of Laparoscopic Surgical Systems for Gynaecological Surgery

Clinical Trial Protocol to Evaluate the Efficacy and Safety of Laparoscopic Surgical Systems for Gynaecological Surgery

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06598085
Enrollment
20
Registered
2024-09-19
Start date
2024-07-01
Completion date
2025-01-20
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Endometrial Cancer

Keywords

Cervical Cancer, Endometrial Cancer

Brief summary

Evaluation of the efficacy and safety of thoracic and abdominal endoscopic surgical systems manufactured by Shenzhen Cornerstone Robotics Technology Co., Ltd. for use ingynaecological surgical procedures.

Detailed description

The trial was designed using a prospective, single-centre, single-group target value approach. For subjects who intend to undergo gynaecological surgery assisted by the Thoracic and Abdominal Endoscopic Surgical System. To use the Thoracic and Abdominal Endoscopic Surgical System developed by Shenzhen Cornerstone Robotics Technology Co., Ltd. to perform surgery , and to evaluate the efficacy and safety of the experimental medical device in the surgical treatment

Interventions

Surgery with the Cornerstone Surgical Robot.

Sponsors

Cornerstone Robotics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 and ≤ 80 years; * Body Mass Height Index (BMI) 18\<BMI\<30kg/㎡; * Patients identified by the investigator as suitable for general, gynaecological and thoracic surgery; * Written informed consent.

Exclusion criteria

* Need for emergency surgery (e.g. gastric cancer, colorectal cancer combined with perforation, bleeding, obstruction, etc.); * With other malignancies or a previous history of other malignancies. * Preoperative imaging suggests that the tumour has distant metastases. * The patient has a history of relevant surgery or previous history of other malignancy and is judged by the investigator to be unsuitable for enrolment. * Severe bleeding tendencies or coagulopathic disorders. * With long-term use of anticoagulant and anti-platelet drugs (anti-platelet aggregation drugs discontinued less than 1 week prior to surgery), history of bleeding disorders or hematopoietic or coagulation disorders. * Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids). * With severe allergies and suspected or established alcohol, drug or substance addiction. * Other conditions which, in the opinion of the investigator, make participation in this trial inappropriate.

Design outcomes

Primary

MeasureTime frameDescription
Surgical non-referral rateDuring the surgerySurgical untransferred is defined as not converted from an experimental medical device assisted method to another surgical device control system assisted, laparoscopic surgery or open surgery.

Secondary

MeasureTime frameDescription
The surgeon's operating timeDuring the surgeryOperative time(minutes)
Intraoperative blood lossDuring the surgeryEstimated blood loss(milliliters,ml)
Length of postoperative stayup to 12 weeksTotal number of days the patient was in hospital from the day of surgery to discharge.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026